Late detection of cancer often leads to increased morbidity and mortality, as many cancers are not detected early. Currently available biomarkers and diagnostic methods lack sensitivity and specificity in detecting cancer at an early stage, and are often invasive and unsuitable for follow-up in healthy individuals.
To address this problem, our scientists have developed a new method for detecting cancer using a multiple cancer blood test. By analyzing DNA methylation patterns in normal tissues, blood, and cancer from thousands of individuals, we have identified methylation profiles that are distinct between cancer and normal tissues. Our proprietary method, called BCD (Binary Categorical Differentiation), uses these profiles to identify clear differences between cancer and normal tissues.
The BCD method employs a binary approach to categorize the methylation profiles, making it easy to distinguish between cancer and normal tissues. This innovative approach has the potential to revolutionize cancer diagnosis and could lead to earlier detection, improving patient outcomes.
